• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Inflazyme Pharmaceuticals Ltd., To Appear On MN1.Com Today

Posted on: Thursday, 11 January 2007, 12:01 CST

REMINDER, Jan. 11, 2007 (PRIME NEWSWIRE) -- Dr. Kevin Mullane, President and CEO of Inflazyme Pharmaceuticals Ltd. (Other OTC:IZYPF) (TSX:IZP), will be featured live on Market News First (www.mn1.com) for an exclusive interview with the MN1 news team. The interview is scheduled today, at 11 a.m. CST. Dr. Mullane will provide an overview of the company, a summary of the corporate goals as well as its future value drivers in the stock market.

Inflazyme Pharmaceuticals is engaged in the discovery, development and commercialization of innovative therapies for the treatment of respiratory and inflammatory diseases using medicinal chemistry based, orally active, small molecules. The Company's strategy is to develop first or best-in-class therapies for large and growing markets and collaborate with large pharmaceutical or biotechnology companies for late-stage development and commercialization.

Inflazyme has two products in Phase II clinical studies: IPL512,602 in asthma and IPL455,903 in learning and memory disorders. The results of both of these clinical studies are expected in the first quarter of 2007. The company also has two other clinical stage products and three early stage programs which are currently on hold due to resource constraints.

IPL512,602 is a proprietary, novel drug of the class called leukocyte selective anti-inflammatory drugs (LSAIDs(tm)). It is an oral, anti-inflammatory compound that targets the lungs. It is being tested as an oral, once a day tablet in patients with moderate to severe asthma. Over 200 patients have been enrolled in the Phase IIb study which started in May 2006 and enrollment was completed in November 2006. Top line results are expected during the first part of Q1 2007.

IPL455,903 is a PDE4 inhibitor discovered and patented by Inflazyme. Inflazyme entered into a Limited License with Helicon Therapeutics, Inc. which allows Helicon to develop the compound in the areas of learning and memory disorders. Inflazyme has been advised that the results of the Phase IIa proof of concept study with IPL455,903 in Age Associated Memory Impairment (AAMI) are expected in the first quarter of 2007.

Inflazyme's proprietary class of PDE4 Inhibitors, which could also be used to treat asthma and COPD, do not cause nausea or emesis (vomiting) in human subjects in clinical studies or vasculitis (inflammation of the blood vessels in the body) in preclinical studies. These compounds are at the research stage and could be readily advanced into the clinic.

About MN1.com

Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.

Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

The Market News First logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3162

This news release was distributed by PrimeNewswire, www.primenewswire.com

CONTACT: Inflazyme Pharmaceuticals Ltd. Julie Rezler, Sr. Director, Corporate Development (800) 315-3660 (604) 279-8511 Fax: (604) 279-8711 ir@inflazyme.com www.inflazyme.com

Source: PrimeNewswire

More News in this Category